ARDS患者俯卧位通气的前瞻性国际观察性患病率研究:APRONET(ARDS俯卧位网络)研究
APRONET研究是一项前瞻性国际1日患病率研究,于2016年4月、7月、10月和2017年1月共4次调查,在20个国家141个ICU中筛查6723例患者,其中735例ARDS患者纳入分析。总体101例ARDS患者至少接受一次俯卧位通气(13.7%),轻度、中度、重度ARDS使用率分别为5.9%(11/187)、10.3%(41/399)和32.9%(49/149)(P=0.0001)。首次俯卧位通气中位时长18(16-23)小时,仰卧位测量PaO2/FIO2从101(76-136)升至171(118-220)mmHg(P=0.0001),驱动压从14(11-17)降至13(10-16)cmH2O(P=0.001),平台压从26(23-29)降至25(23-28)cmH2O(P=0.04)。未使用俯卧位通气最常见原因为低氧血症被认为不够严重(64.3%),使用俯卧位通气的患者中12例(11.9%)报告并发症。
要点
- 重度ARDS患者俯卧位通气使用率仅32.9%(49/149),轻度5.9%(11/187)、中度10.3%(41/399),使用率随ARDS严重程度递增(P=0.0001)。
- 未使用俯卧位通气最常见原因是低氧血症被认为不够严重,占64.3%。
- 首次俯卧位通气中位时长18(16-23)小时,仰卧位测量PaO2/FIO2从101(76-136)升至171(118-220)mmHg(P=0.0001)。
- 俯卧位通气后驱动压从14(11-17)降至13(10-16)cmH2O(P=0.001),平台压从26(23-29)降至25(23-28)cmH2O(P=0.04)。
- 使用俯卧位通气的患者中12例(11.9%)报告并发症:压疮5例、低氧血症2例、气管插管相关2例、眼部2例、颅内压短暂升高1例。
适用人群与场景
- 在20个国家141个ICU(77%为欧洲ICU)中筛查的ARDS患者,共735例纳入分析。
- 研究在2016年4月、7月、10月和2017年1月共4个研究日进行,每个研究日筛查每个ICU的所有患者。
诊断标准与关键阈值
- ARDS诊断由各ICU研究者判断,研究记录了ARDS患者的俯卧位通气使用、气体交换、呼吸机设置和平台压。
处置流程与药物剂量
- 对ARDS患者记录俯卧位通气使用情况,并在俯卧位通气 session 前和结束时记录气体交换、呼吸机设置和平台压。
- 首次俯卧位通气 session 的中位时长为18(16-23)小时。
红旗征与不能漏的情况
- 俯卧位通气相关并发症:压疮5例、低氧血症2例、气管插管相关2例、眼部2例、颅内压短暂升高1例(共12例,11.9%)。
研究设计与关键结果
- 研究类型:前瞻性国际1日患病率研究,共4次调查;样本量:筛查6723例,735例ARDS患者纳入分析;141个ICU,20个国家(77%为欧洲ICU)。
- 主要终点:总体101例ARDS患者至少接受一次俯卧位通气(13.7%),4个研究日之间无差异;轻度、中度、重度ARDS使用率分别为5.9%(11/187)、10.3%(41/399)、32.9%(49/149)(P=0.0001)。
- 首次俯卧位通气中位时长18(16-23)小时;仰卧位测量PaO2/FIO2从101(76-136)升至171(118-220)mmHg(P=0.0001)。
- 驱动压从14(11-17)降至13(10-16)cmH2O(P=0.001),平台压从26(23-29)降至25(23-28)cmH2O(P=0.04)。
- 未使用俯卧位通气最常见原因为低氧血症被认为不够严重(64.3%);使用俯卧位通气的患者中12例(11.9%)报告并发症。
证据类型、等级与局限
- 证据类型:前瞻性国际观察性患病率研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 研究显示重度ARDS患者俯卧位通气使用率为32.9%,轻中度使用率更低,未使用最常见原因是低氧血症被认为不够严重(64.3%)。
- 俯卧位通气与PaO2/FIO2升高、驱动压和平台压降低相关,并发症报告率为11.9%。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: While prone positioning (PP) has been shown to improve patient survival in moderate to severe acute respiratory distress syndrome (ARDS) patients, the rate of application of PP in clinical practice still appears low.
AIM: This study aimed to determine the prevalence of use of PP in ARDS patients (primary endpoint), the physiological effects of PP, and the reasons for not using it (secondary endpoints).
METHODS: The APRONET study was a prospective international 1-day prevalence study performed four times in April, July, and October 2016 and January 2017. On each study day, investigators in each ICU had to screen every patient. For patients with ARDS, use of PP, gas exchange, ventilator settings and plateau pressure (Pplat) were recorded before and at the end of the PP session. Complications of PP and reasons for not using PP were also documented. Values are presented as median (1st-3rd quartiles).
RESULTS: Over the study period, 6723 patients were screened in 141 ICUs from 20 countries (77% of the ICUs were European), of whom 735 had ARDS and were analyzed. Overall 101 ARDS patients had at least one session of PP (13.7%), with no differences among the 4 study days. The rate of PP use was 5.9% (11/187), 10.3% (41/399) and 32.9% (49/149) in mild, moderate and severe ARDS, respectively (P = 0.0001). The duration of the first PP session was 18 (16-23) hours. Measured with the patient in the supine position before and at the end of the first PP session, PaO2/FIO2 increased from 101 (76-136) to 171 (118-220) mmHg (P = 0.0001) driving pressure decreased from 14 [11-17] to 13 [10-16] cmH2O (P = 0.001), and Pplat decreased from 26 [23-29] to 25 [23-28] cmH2O (P = 0.04). The most prevalent reason for not using PP (64.3%) was that hypoxemia was not considered sufficiently severe. Complications were reported in 12 patients (11.9%) in whom PP was used (pressure sores in five, hypoxemia in two, endotracheal tube-related in two ocular in two, and a transient increase in intracranial pressure in one).
CONCLUSIONS: In conclusion, this prospective international prevalence study found that PP was used in 32.9% of patients with severe ARDS, and was associated with low complication rates, significant increase in oxygenation and a significant decrease in driving pressure.
参考来源
- Guérin C, Beuret P, Constantin JM, et al. A prospective international observational prevalence study on prone positioning of ARDS patients: the APRONET (ARDS Prone Position Network) study. Intensive Care Med. 2017. PMID: 29218379. doi:10.1007/s00134-017-4996-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。